Raras
Buscar doenças, sintomas, genes...
Síndrome de neuroléptico maligno
ORPHA:94093CID-10 · G21.0CID-11 · 8A0YDOENÇA RARA

A síndrome neuroléptica maligna (SNM) é uma condição idiossincrática associada à administração de antipsicóticos e outros bloqueadores dopaminérgicos centrais e caracterizada por hipertermia, rigidez muscular, disfunção autonômica e alteração da consciência.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A síndrome neuroléptica maligna (SNM) é uma condição idiossincrática associada à administração de antipsicóticos e outros bloqueadores dopaminérgicos centrais e caracterizada por hipertermia, rigidez muscular, disfunção autonômica e alteração da consciência.

Publicações científicas
2.592 artigos
Último publicado: 2026 Apr 17

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G21.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
4 sintomas
❤️
Coração
3 sintomas
🧠
Neurológico
3 sintomas
💪
Músculos
3 sintomas
🫘
Rins
3 sintomas
🩸
Sangue
3 sintomas

+ 32 sintomas em outras categorias

Características mais comuns

90%prev.
Hiperidrose
Muito frequente (99-80%)
90%prev.
Fisiologia anormal do sistema nervoso autônomo
Muito frequente (99-80%)
90%prev.
Consciência/confusão reduzida
Muito frequente (99-80%)
90%prev.
Febre
Muito frequente (99-80%)
90%prev.
Mutismo
Muito frequente (99-80%)
90%prev.
Rigidez muscular extrapiramidal
Muito frequente (99-80%)
54sintomas
Muito frequente (6)
Frequente (11)
Ocasional (33)
Muito raro (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 54 características clínicas mais associadas, ordenadas por frequência.

HiperidroseHyperhidrosis
Muito frequente (99-80%)90%
Fisiologia anormal do sistema nervoso autônomoAbnormal autonomic nervous system physiology
Muito frequente (99-80%)90%
Consciência/confusão reduzidaReduced consciousness/confusion
Muito frequente (99-80%)90%
FebreFever
Muito frequente (99-80%)90%
MutismoMutism
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico2.592PubMed
Últimos 10 anos200publicações
Pico202587 papers
Linha do tempo
2026Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome de neuroléptico maligno

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

15 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
694 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 694

#1

Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database.

PloS one2026

Mirtazapine is widely used in the treatment of major depressive disorder (MDD), yet its real-world safety profile remains insufficiently evaluated. This study analyzed adverse event (AE, plural AEs) reports related to mirtazapine from the FDA Adverse Event Reporting System (FAERS) database between the first quarter of 2004 and the first quarter of 2025. Four disproportionality analysis methods were employed, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Additional analyses included sensitivity analysis, time-to-onset (TTO) evaluation, and Weibull distribution modeling. A total of 17,953 reports were included, with females accounting for 54.1% and males for 37.7%. In 48.4% of the reports, patients were aged between 18 and 65 years. Overall, 65.0% of the reports were submitted by healthcare professionals. Known AEs such as somnolence (n = 887, ROR = 4.57, PRR = 4.52, EBGM = 4.50, IC = 2.17), QT interval prolongation (n = 259, ROR = 7.35, PRR = 7.32, EBGM = 7.27, IC = 2.86), suicidal ideation (n = 601, ROR = 6.65, PRR = 6.59, EBGM = 6.55, IC = 2.71), and rhabdomyolysis (n = 146, ROR = 3.66, PRR = 3.65, EBGM = 3.64, IC = 1.87) showed positive signals. In addition, several unexpected AEs also exhibited positive signals, including restless legs syndrome (n = 305, ROR = 17.05, PRR = 16.97, EBGM = 16.65, IC = 4.06), neuroleptic malignant syndrome (n = 158, ROR = 13.77, PRR = 13.74, EBGM = 13.53, IC = 3.76), and nightmare (n = 279, ROR = 8.02, PRR = 7.99, EBGM = 7.93, IC = 2.99). TTO analysis showed that 59.52% of AEs occurred within the first month of treatment. The results of the sensitivity analyses further supported the robustness of these findings. This study systematically assessed the long-term safety profile of mirtazapine using 21 years of real-world pharmacovigilance data from the FAERS database. The findings provide important evidence to support safe clinical use of mirtazapine and emphasize the need for continuous safety monitoring.

#2

Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.

Brain : a journal of neurology2026 Jan 08

Psychomotor retardation, defined as generalized slowing of movement and speech, is a feature of several neurological and psychiatric disorders. In this review, we discuss the hypothesis that reduced striatal dopaminergic transmission is a transdiagnostic substrate for psychomotor retardation underlying the motor features of conditions such as Parkinson's disease, drug-induced parkinsonism, neuroleptic malignant syndrome, catatonia and depression. We examine the evidence across clinical, epidemiological, neuroimaging, laboratory and therapeutic studies. Parkinsonian disorders share slowed movement and a reduction in verbal output with catatonia and depression. Bradyphrenia, slowed cognitive processing, also occurs in Parkinson's disease and depression. In addition, there are close epidemiological relationships between depression and Parkinson's disease, and between catatonia and neuroleptic malignant syndrome. Neuroimaging studies also generally support the association of psychomotor retardation with reduced dopaminergic transmission, particularly in the dorsal striatum. CSF measurement of homovanillic acid (a dopamine catabolite) yields inconsistent results and is non-specific. Parkinson's disease and catatonia generally respond well to dopaminergic medication. In contrast, dopamine antagonists can induce both parkinsonism and catatonia. Our review is limited by the variability in measurement of psychomotor retardation and difficulty distinguishing between cognitive and motor slowing. It is also likely that other neurotransmitters, such as GABA and serotonin, play an important role in psychomotor speed. It is possible that dopaminergic deficits in psychiatric disorders represent functional disruptions, in contrast to the structural damage to the substantia nigra in Parkinson's disease. We propose further research be conducted into the effects of levodopa and dopamine agonists in depression with psychomotor retardation. Alternative neuroimaging methods such as PET sequences with shorter imaging protocols and neuromelanin-MRI should also be explored.

#3

A Prospective 1-Year Study of Renal Recovery in Pigment Nephropathy: Insights Beyond the Acute Phase.

The Journal of the Association of Physicians of India2026 Mar

Pigment nephropathy is an underrecognized cause of acute kidney injury. Data from northern India is scarce. The present study aims to assess the clinical characteristics and outcomes of pigment nephropathy in this region. We analyzed the demographics, etiology, and outcomes of 20 patients with biopsy-proven pigment nephropathy. The mean age was 27.75 years (range: 13-52), with a male-to-female ratio of 18:2. The average peak serum creatinine was 12.09 mg/dL (range: 0.84-22.3). Rhabdomyolysis was identified in 14 (70%) and hemolysis in 6 patients (30%). The rhabdomyolysis was attributed to hypokalemia, infection, strenuous exercise, physical trauma, inflammatory myositis, neuroleptic malignant syndrome, and heat stroke. The hemolysis was caused by paroxysmal nocturnal hemoglobinuria, thrombotic microangiopathy, transfusion reaction, rifampicin, and physical stress. The majority of patients (85%) required hemodialysis, with a mean of 6 sessions (range: 3-17). The mean duration of hospitalization was 15.3 days (range: 4-30), and the average time to renal recovery was 3.1 weeks (range: 2-6). All 20 patients survived and achieved complete renal recovery. Of the 20 patients, 13 completed at least 1 year of follow-up, 4 were lost to follow-up, and 3 remain under observation. At 1 year, all 13 patients had normal serum creatinine. None progressed to chronic kidney disease. Of 20 patients (4.1%) with pigment-induced acute kidney injury (AKI), 70% had myoglobin- and 30% hemoglobin-induced nephropathy. Common causes included hypokalemia, infection, strenuous activity, and paroxysmal nocturnal hemoglobinuria. Hemodialysis was required in 85%, with an average hospital stay of 15.3 days. Among 13 patients with a 1-year follow-up, none developed chronic kidney disease. Overall prognosis appears favorable; however, larger studies with extended follow-up are needed to better characterize long-term outcomes in pigment nephropathy.

#4

Effectiveness of Transdermal Blonanserin Patch for Hyperactive Delirium in Patients with Advanced Cancer Receiving Palliative Care.

Journal of palliative medicine2026 Mar 01

Delirium affects most patients with advanced cancer and is a major source of distress, especially in its hyperactive subtype. Pharmacologic options are limited for patients who cannot take oral medications. To evaluate the effectiveness and safety of a transdermal blonanserin patch for managing hyperactive delirium in patients with advanced cancer admitted to a palliative care unit. Retrospective observational study. Consecutive patients with advanced cancer admitted to a palliative care unit in Japan between July 2023 and July 2025. Among 60 patients exhibiting agitation (Richmond Agitation-Sedation Scale-Palliative Version [RASS-PAL] ≥ +1), 21 received a 40-mg blonanserin patch. Eighteen patients who completed the 7-day assessment were analyzed. The primary endpoint was the change in RASS-PAL score from day 0 to day 7. Safety events and the need for additional antipsychotics were recorded. The median RASS-PAL score decreased from 2.0 to 0.5, and the mean score decreased from 1.9 to 0.6 (p = 0.0019). One patient developed reversible excessive sedation. No extrapyramidal symptoms, neuroleptic malignant syndrome, or cardiopulmonary events occurred. The median time from patch initiation to death was 24 days. Five patients required rescue antipsychotics, and no recurrence of the initial severity of delirium was observed. The transdermal blonanserin patch appears to be an effective and well-tolerated option for hyperactive delirium in patients with advanced cancer who cannot take oral antipsychotics. Larger prospective studies are warranted to confirm effectiveness and guide optimal use.

#5

Case Report: Atypical neuroleptic malignant syndrome induced by paliperidone palmitate-diagnostic challenges and clinical considerations.

Frontiers in psychiatry2026

Poor treatment adherence is common in schizophrenia and constitutes a major risk factor for relapse and clinical instability. Long-acting injectable (LAI) antipsychotics are frequently prescribed to mitigate this risk; however, their use can be associated with rare but serious adverse events, including neuroleptic malignant syndrome (NMS), with certain atypical presentations posing considerable diagnostic challenges. We report the case of a 51-year-old patient with schizophrenia who, during hospitalization for a psychotic relapse following prolonged refusal of all oral medications, received an intramuscular injection of paliperidone palmitate. Within a few days, the patient experienced a rapid clinical deterioration, characterized by hyperthermia (38 °C), tachycardia (120 bpm), generalized muscular rigidity, mutism, confusion, dehydration, and refusal of oral intake. No obvious precipitating factors, including infectious or environmental triggers, were identified. Initial laboratory workup revealed marked creatine phosphokinase elevation (1700 U/L), hyperferritinemia, and evidence of a pulmonary infiltrate on chest imaging. Given this constellation of clinical and laboratory findings, a diagnosis of neuroleptic malignant syndrome (NMS) was considered. The lack of improvement with antibiotic therapy alone, the persistence of extrapyramidal symptoms, and the ongoing laboratory abnormalities supported the diagnosis of an atypical form of NMS. The patient was transferred to the intensive care unit, where symptomatic management-including intravenous rehydration, antipyretics, empirical antibiotic therapy, and diazepam-resulted in gradual clinical improvement. Complete recovery was achieved after five weeks of hospitalization. Antipsychotic therapy was cautiously reintroduced with olanzapine, which was well tolerated and not associated with any recurrence of symptoms. This case illustrates the diagnostic and therapeutic challenges of neuroleptic malignant syndrome associated with long-acting injectable antipsychotics and emphasizes the need for close and prolonged monitoring in patients receiving these formulations.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.993 artigos no totalmostrando 198

2026

Malignant Catatonia and Neuroleptic Malignant Syndrome Overlap in the Emergency Department: Diagnostic Challenges and Psychopharmacology Considerations.

Journal of clinical psychopharmacology
2026

A Prospective 1-Year Study of Renal Recovery in Pigment Nephropathy: Insights Beyond the Acute Phase.

The Journal of the Association of Physicians of India
2026

Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database.

PloS one
2026

Effectiveness of Transdermal Blonanserin Patch for Hyperactive Delirium in Patients with Advanced Cancer Receiving Palliative Care.

Journal of palliative medicine
2026

Case Report: Atypical neuroleptic malignant syndrome induced by paliperidone palmitate-diagnostic challenges and clinical considerations.

Frontiers in psychiatry
2026

Intensive Care Management and Outcomes of Neuroleptic Malignant Syndrome: A Single-Center Retrospective Study.

Medicina (Kaunas, Lithuania)
2026

Neuroleptic Malignant Syndrome Induced by Multiple Antipsychotics in a Patient Receiving Methadone.

Cureus
2026

Promethazine-induced neuroleptic malignant syndrome under general anesthesia: a case report.

Frontiers in psychiatry
2026

Sertraline and quetiapine induced Serotonin Syndrome and Neuroleptic Malignant Syndrome: a case report.

BMC psychiatry
2026

Ultrabrief and Brief Pulse Right Unilateral Electroconvulsive Therapy for Catatonia Management and Relapse Prevention: Naturalistic Case Series.

The journal of ECT
2026

Clinical Outcomes of Dantrolene in Neuroleptic Malignant Syndrome: A Nationwide Retrospective Study.

Acta psychiatrica Scandinavica
2026

Co-occurrence of Neuroleptic Malignant Syndrome and Silent Syndrome in a Patient With Bipolar Disorder: Clinical Challenges and Long-term Neurological Sequelae.

Cerebellum (London, England)
2026

Parkinsonism Exacerbation due to Acute Dopamine Depletion: A Conundrum Revisited.

Movement disorders clinical practice
2026

Neurological Adverse Effects of Antipsychotic Medication in Children and Young People.

Paediatric drugs
2025

Clinical Outcomes and Factors Associated with Neuroleptic Malignant Syndrome in Older Patients: A Case Control Study.

Journal of clinical medicine
2025

Neuroleptic Malignant Syndrome Unmasked: A Case of Extrapyramidal Syndrome With Tardive Dystonia Leading to a Life-Threatening Crisis.

Cureus
2025

Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a Pediatric Patient Receiving Fluoxetine and Haloperidol: A Case Report.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
2025

Systematic analysis of adverse reactions associated with dantrolene treatment: From clinical features to molecular mechanisms.

Medicine
2025

Neuroleptic Malignant Syndrome on Chronic Trifluoperazine Therapy: A Diagnostic Dilemma.

Clinical case reports
2025

From Varenicline to Neuroleptic Malignant Syndrome: The Complex Effects of Smoking Cessation on Dopamine Regulation.

The primary care companion for CNS disorders
2025

Letter: Low CK, High Suspicion: A Case of Atypical Neuroleptic Malignant Syndrome in a Pediatric Post-Transplant Patient.

Journal of child and adolescent psychopharmacology
2025

Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome: A Case Report.

Cureus
2025

Serotonin syndrome: understanding pathophysiological bases and managing a growing clinical challenge.

Neurologia i neurochirurgia polska
2025

[Experience of Neuroleptic Malignant Syndrome After Operation:Total Arch Replacement for Stanford Type A Acute Aortic Dissection:Report of a Case].

Kyobu geka. The Japanese journal of thoracic surgery
2025

Dantrolene use across surgical and medical care at Mayo Clinic from 2010 to 2024: Indications, frequency, and value for identifying malignant hyperthermia.

Biomolecules &amp; biomedicine
2025

Lorazepam in Managing Atypical Neuroleptic Malignant Syndrome: A Systematic Review of Case Reports.

The western journal of emergency medicine
2025

A Diagnostic Dilemma-Severe Hyperthermia and Rigidity in a Young Man with Polysubstance Use: A Case Report.

Clinical practice and cases in emergency medicine
2025

Anesthetic implications of psychotropic medications: a narrative review.

Journal of Yeungnam medical science
2025

Neurological Emergencies in Incarcerated Patients: Clinical Characteristics, Severity, and Outcomes in an Emergency Department with an Embedded Neuro-Emergency Expert Model.

Brain sciences
2025

Development of Neuroleptic Malignant Syndrome After Administration of Clozapine and Electroconvulsive Therapy in a Patient With Schizophrenia.

The primary care companion for CNS disorders
2025

Beyond Infections: A Case Report on the Identification of Neuroleptic Malignant Syndrome (NMS) in a Complex Clinical Context.

Clinical case reports
2025

Neuroleptic Malignant Syndrome: A Case Report of the Oldest Man in Literature.

Clinical case reports
2025

Neuroleptic Malignant Syndrome with Low-dose Quetiapine After Venlafaxine Withdrawal: A Case Report.

Turk psikiyatri dergisi = Turkish journal of psychiatry
2025

Neuroleptic malignant syndrome and clozapine withdrawal-induced catatonia: a case report.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan
2025

A Real-World Pharmacovigilance study of FAERS Database for Fluvoxamine: Perspectives from Physicians and Pharmacists.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
2025

Three Episodes of Neuroleptic Malignant Syndrome With Risperidone: A Case Report and Literature Review.

Case reports in psychiatry
2026

Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.

Brain : a journal of neurology
2025

Trauma-induced Catatonia in Pediatric Patients: Case Series and Literature Review.

Journal of child &amp; adolescent trauma
2025

Probable Autoimmune Encephalitis Presenting With Catatonia in a Young Woman: A Case Report and Review of the Literature.

International journal of psychiatry in medicine
2025

Three Distinct Neuropsychiatric Syndromes Following Pineal Teratoma Resection.

Journal of child and adolescent psychopharmacology
2025

A Narrative Review on Toxidromes in the Psychiatric Population: Implications for Overdose Prevention.

Journal of clinical medicine
2025

Dealing with the dilemma of an encounter with neuroleptic malignant syndrome in an adolescent with mania: A case report.

Indian journal of psychiatry
2025

Neuroleptic Malignant Syndrome in an Institutionalized Geriatric Patient Following Antipsychotic Switch to Quetiapine: A Fatal Outcome.

Cureus
2026

Emergency Treatment of Neuroleptic Malignant Syndrome By a Remote Mobile Electroconvulsive Therapy (ECT) Team.

The journal of ECT
2025

Concurrence of clozapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome: A case report.

Medicine
2025

Catatonia in a Possible Case of Moderate Neuroleptic Malignant Syndrome: A Case Report.

Reports (MDPI)
2025

A Fatal Case of Recurrent Neuroleptic Malignant Syndrome Without Hyperthermia With the Use of Second-Generation Antipsychotics.

Journal of clinical psychopharmacology
2025

A case of anti-N-methyl-D-aspartate receptor encephalitis with associated ovarian teratoma in a 23-year-old female.

Radiology case reports
2026

An unusual case of neuroleptic malignant syndrome.

Tropical doctor
2025

An Analytic Review of Neuropsychiatric Syndromes in the Intensive Care Unit.

Journal of intensive care medicine
2025

Atypical Neuroleptic Malignant Syndrome Without Rigidity and With Cardiac Troponin Elevation.

Journal of the Academy of Consultation-Liaison Psychiatry
2025

A practical approach to managing agitated toxidromes.

Tropical doctor
2025

Anti-N-Methyl-D-Aspartate Receptor Encephalitis Presenting as Isolated First-Episode Psychosis in A 16-Year-Old Girl, Complicated by Neuroleptic Malignant Syndrome.

European journal of case reports in internal medicine
2025

Severe Catatonia in Early-Onset Schizophrenia Successfully Treated With Lorazepam and Aripiprazole in a 16-Year-Old Girl: A Case Report.

Cureus
2025

A Young Man with Altered Mental Status, Rigidity, and Hyperthermia.

The Neurohospitalist
2025

Neuroleptic Malignant Syndrome: A Retrospective Chart Review from a Tertiary Neuropsychiatric Facility.

Neurology India
2025

Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese adverse drug event report database (2008-2024).

European journal of pharmacology
2025

Is Abrupt Withdrawal of Benzodiazepines a Risk Factor for Neuroleptic Malignant Syndrome? A Case Report With Single-Dose Haloperidol.

Clinical case reports
2025

Successful treatment with lithium carbonate for periodic psychosis of adolescence.

PCN reports : psychiatry and clinical neurosciences
2025

Neuroleptic malignant syndrome: A case report.

JPMA. The Journal of the Pakistan Medical Association
2025

Letter: Seventeen-Year-Old Develops Neuroleptic Malignant Syndrome after Brief Low-Dose Exposure to Aripiprazole: A Case Report.

Journal of child and adolescent psychopharmacology
2025

Case Report: Neuroleptic malignant syndrome in a 15-year-old female following of psychotropic drugs.

Frontiers in psychiatry
2025

[Fahr's disease and mania: case report and literature review].

Tijdschrift voor psychiatrie
2025

Neuroleptic malignant syndrome in a patient with COVID-19 and the possible role of SARS-CoV-2 in its manifestation: case report and overview of published cases.

BMC psychiatry
2025

Acute Febrile Encephalopathy with Rigidity.

Journal of intensive care medicine
2025

Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report.

Cureus
2025

Investigation into neuroleptic malignant syndrome triggered by atypical antipsychotics: Insights from FDA adverse event reporting system database.

Journal of affective disorders
2025

Diagnostic Value of Botryoid Nuclei as a Biomarker of Severe Hyperthermia and Systemic Inflammation in Heatstroke and Neuroleptic Malignant Syndrome: A Challenge of Climate Change.

International journal of laboratory hematology
2025

Catatonia: American Psychiatric Association Resource Document.

Journal of the Academy of Consultation-Liaison Psychiatry
2025

Alcohol-Induced Neuroleptic Malignant Syndrome Complicated by Severe Acute Rhabdomyolysis.

Cureus
2025

Benzodiazepine and Opioid Withdrawal Induced Neuroleptic Malignant Like Syndrome: A Clinical Case Report With Management Complexities.

Neuropsychopharmacology reports
2025

Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy.

Schizophrenia research
2025

Neuroleptic malignant syndrome requiring intensive care unit admission in two patients with SARS-CoV-2 infection in Portugal.

Acute and critical care
2025

Neuroleptic malignant syndrome induced by donepezil in a patient treated with risperidone and trazodone.

BMJ case reports
2025

Rhabdomyolysis and Acute Kidney Injury: Exploring the Potential Causes in a Hospitalized Patient.

Cureus
2025

Reversible Splenial Lesion Syndrome Induced by Paracetamol and Lithium: A Report of Two Cases and Literature Review.

Cureus
2025

Hypothermia and fluctuations in body temperature should be considered for the positive diagnosis of Neuroleptic Malignant Syndrome.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
2025

Misdiagnosis and high-dose polypharmacy-induced neuroleptic malignant syndrome: a case report.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan
2025

Parkinsonism Hyperpyrexia Syndrome: A Rare Cause of Temperature Elevation.

Cureus
2025

Paliperidone-induced neuroleptic malignant syndrome: A case report.

Medicine
2025

A case of modified electroconvulsive therapy for a patient with dementia with Lewy bodies and neuroleptic malignant syndrome.

Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society
2025

Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database.

Journal of clinical psychopharmacology
2025

Paliperidone-Induced Massive Asymptomatic Creatine Kinase Elevation in Youth: From a Case Report to Literature Review.

Pediatric reports
2025

Raised Creatine Kinase with Numerous Antipsychotics Responded to Clozapine.

Psychopharmacology bulletin
2025

Increased incidence of akinetic crises in Parkinson's disease patients treated with Levodopa-Carbidopa Intestinal Gel: A case series and review of the literature.

Clinical neurology and neurosurgery
2025

Genomic exploration of pediatric neurological disorders: a case series.

Journal of medical case reports
2025

COVID-19 and Neuroleptic Malignant Syndrome: A Case Report and Review of Literature.

Journal of clinical psychopharmacology
2025

A Case of Euglycemic Ketoacidosis Secondary to Continuous Renal Replacement Therapy.

Case reports in critical care
2025

A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy.

BMC psychiatry
2025

Contemporary Perspectives in Critical Care of Neuroleptic Malignant Syndrome.

Neurocritical care
2025

Bromocriptine for Residual Catatonia Following Neuroleptic Malignant Syndrome: Illustrative Case Report and Systematic Review.

Journal of the Academy of Consultation-Liaison Psychiatry
2025

Bilingual side effect: a case of foreign language syndrome following chlorpromazine-induced neuroleptic malignant syndrome.

Annals of general psychiatry
2024

A real-world pharmacovigilance study of neuroleptic malignant syndrome based on FDA adverse event reporting system.

Frontiers in pharmacology
2024

The limited clinical utility of a routine creatine kinase (CK) on admission to a psychiatric inpatient unit.

BMC psychiatry
2024

Diagnostic Challenges in Malignant Hyperthermia and Anesthesia-Induced Rhabdomyolysis: A Case Study.

The American journal of case reports
2024

Inflammation-Related Non-Infectious Febrile Reaction Induced by Electroconvulsive Therapy in a Young Female with Bipolar Disorder: A Case Report and Literature Review.

Psychiatry and clinical psychopharmacology
2025

Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data.

European child &amp; adolescent psychiatry
2024

Lamotrigine as a preventive agent against recurrent catatonia in adult-onset Niemann-Pick Type-C disease: a case report.

Neurocase
2025

Signal mining and risk analysis of olanzapine adverse events in the FAERS database.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
2024

The broad spectrum of malignant syndromes.

Neurobiology of disease
2024

Neuroleptic Malignant Syndrome in a 10-Month-Old Ex-Preterm Infant with Delirium.

AJP reports
2024

Anti-NMDAR Encephalitis developing neuroleptic malignant syndrome.

Industrial psychiatry journal
2025

Use of Electroconvulsive Therapy on an Adolescent Inpatient Psychiatric Unit.

Child and adolescent psychiatric clinics of North America
2024

Neuroleptic malignant syndrome in Huntington disease.

European journal of neurology
2024

Bipolar Disorder in a Young Adult With Thalassemia Major With Sequential Development of Neuroleptic Malignant Syndrome and Serotonin Syndrome.

Journal of clinical psychopharmacology
2025

Expert guidance on the differential diagnosis of neuroleptic malignant syndrome.

Expert review of neurotherapeutics
2024

Acute kidney injury induced lithium toxicity with concomitant neuroleptic malignant syndrome.

BioMedicine
2024

A Case of Neuroleptic Malignant Syndrome-Prompted Myoglobin Cast Nephropathy.

Indian journal of nephrology
2024

Psychiatric Etiologies and Approaches in Altered Mental Status Presentations: Insights from Consultation Liaison Psychiatry.

Seminars in neurology
2024

Evaluation of Antipsychotic-Induced Neuroleptic Malignant Syndrome Using a Self-Organizing Map.

Cureus
2025

Rhythmic Delta Activity beyond Neuroleptic Malignant Syndrome.

Internal medicine (Tokyo, Japan)
2025

Long-Acting Injectable Antipsychotic Medication Use in Youth: A Systematic Review of the Literature Along with MedWatch Safety Data and Prescriber Attitudes.

Journal of child and adolescent psychopharmacology
2024

Neuroleptic Malignant Syndrome.

The New England journal of medicine
2024

Dual Toxidrome of Anti-cholinergic Storm and Neuroleptic Malignant Syndrome: A Therapeutic Challenge Overcome by Intrathecal Neostigmine.

The Neurohospitalist
2024

Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study.

Journal of child and adolescent psychopharmacology
2024

Not Too Rare to Matter: The Incidence of Neuroleptic Malignant Syndrome in Children and Adolescents Treated with Antipsychotics.

Journal of child and adolescent psychopharmacology
2025

Widespread Muscle Calcification due to Neuroleptic Malignant Syndrome.

Internal medicine (Tokyo, Japan)
2025

Life-threatening Neuroleptic Malignant Syndrome and Its Mechanism.

Internal medicine (Tokyo, Japan)
2025

Conceptualizing the relationship between synthetic cannabinoid use and neuroleptic malignant syndrome.

Bipolar disorders
2024

A Series of Eight Cases of Pigment Nephropathy: An Obscured Aspect of Acute Kidney Injury.

Cureus
2024

The Atypical Face of Neuroleptic Malignant Syndrome: A Case Report of Ileus and Absent Rigidity.

Cureus
2023

Infectious disease evaluations in a psychiatric unit, an observational study.

Revista medica de Chile
2024

Atypical Presentation of Ziprasidone-Induced Neuroleptic Malignant Syndrome: A Case Report.

Journal of investigative medicine high impact case reports
2024

Integrating Physiotherapy in Neuroleptic Malignant Syndrome Management: A Case Report.

Cureus
2023

Catatonia: A Narrative Review for Hospitalists.

American journal of medicine open
2025

Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.

Inflammatory bowel diseases
2024

Successful Diagnosis of Neuroleptic Malignant Syndrome in an Unconscious Patient Using Amplitude-Integrated Electroencephalography: A Case Report.

Cureus
2025

Use of En-Bloc Multiple Monitored Electroconvulsive Therapy in Benzodiazepine Refractory Malignant Catatonia.

The journal of ECT
2024

Recurrent Fevers, Dysautonomia, and Dehydration in a Patient With Lesch-Nyhan Syndrome.

Cureus
2024

Neuroleptic malignant syndrome following clozapine withdrawal.

Industrial psychiatry journal
2024

Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy.

BMC psychiatry
2024

Long prodromal symptoms of neuroleptic malignant syndrome in patient with intellectual developmental disorder-A case report.

Neuropsychopharmacology reports
2025

Successful Treatment of Both Refractory Neuroleptic Malignant Syndrome and Subsequent Catatonia With Electroconvulsive Therapy in a Patient With Suspected Kufs Disease.

The journal of ECT
2024

Neuroleptic malignant syndrome and serotonin syndrome: a comparative bibliometric analysis.

Orphanet journal of rare diseases
2024

Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia.

Case reports in psychiatry
2024

Haloperidol-Induced Neuroleptic Malignant Syndrome: A Case Report.

Cureus
2024

Serious adverse drug events associated with psychotropic treatment of bipolar or schizoaffective disorder: a 17-year follow-up on the LiSIE retrospective cohort study.

Frontiers in psychiatry
2024

Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports.

Journal of medical case reports
2024

Neuroleptic Malignant Syndrome: An Intensive Care Unit Case of Exceptionally High Creatinine Kinase and Myoglobin Levels.

Cureus
2024

Prochlorperazine-induced neuroleptic malignant syndrome.

The American journal of emergency medicine
2024

Neuroleptic malignant syndrome after overdose of haloperidol - A case report.

Toxicology reports
2024

Transient Fever Response After ECT in a Patient with Catatonic Schizophrenia: A Case Report.

Turk psikiyatri dergisi = Turkish journal of psychiatry
2024

Neuroleptic Malignant Syndrome Concurrent with COVID-19 Infection: A Case Report.

Turk psikiyatri dergisi = Turkish journal of psychiatry
2024

Mixed Connective Tissue Disease Presenting With Psychosis-A Case Report.

The Journal of nervous and mental disease
2024

An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.

CNS drugs
2024

Parkinsonism-hyperpyrexia, a rare consequence of deep brain stimulator malfunction in advanced Parkinson's disease.

Clinical parkinsonism &amp; related disorders
2023

Neuroleptic malignant syndrome after abrupt discontinuation of neuroleptic and anticholinergic drugs.

Industrial psychiatry journal
2024

Atypical Neuroleptic Malignant Syndrome With Type 2 Respiratory Failure Treated With Non-invasive Ventilation.

Cureus
2024

Atypical neuroleptic malignant syndrome in an incarcerated patient: a demographic who may be at increased risk.

BMJ case reports
2024

First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database.

International journal of clinical pharmacy
2024

Serotonin syndrome and neuroleptic malignant syndrome: A case report of intersecting symptomatology.

The mental health clinician
2024

Catatonia-related adverse outcomes after long-acting injectable antipsychotics: Case series.

SAGE open medical case reports
2023

Hold off That Olanzapine! The Development of Neuroleptic Malignant Syndrome in a Dehydrated Pediatric Patient.

Kansas journal of medicine
2024

Anesthesia Management for Electroconvulsive Therapy.

AANA journal
2023

Parkinsonism-Hyperpyrexia Syndrome in a patient undergoing upper gastrointestinal surgery: A case report.

Qatar medical journal
2023

Subthalamic Deep Brain Stimulation in Parkinson's Disease: A Boon or Bane - A Single Centre Retrospective Observational Study from India.

Asian journal of neurosurgery
2024

Examining the Features of Neuroleptic Malignant Syndrome in Anti-NMDA Receptor Encephalitis: A Case-Control Study.

Journal of the Academy of Consultation-Liaison Psychiatry
2024

Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.

Multiple sclerosis (Houndmills, Basingstoke, England)
2023

Postoperative rhabdomyolysis due to neuroleptic malignant syndrome associated with droperidol and metoclopramide.

Anaesthesiology intensive therapy
2023

When the fever will not stop, stop the pills! A case report.

Sao Paulo medical journal = Revista paulista de medicina
2023

Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system.

Heliyon
2023

Severe Recurrence of Neuroleptic Malignant Syndrome: Usefulness of Dexmedetomidine for Antipsychotic Withdrawal.

Cureus
2023

Challenges in the Clinical Diagnosis of Lithium Toxicity: A Case Report.

Cureus
2023

ATYPICAL NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH MIRTAZAPINE USE.

Psychiatria Danubina
2023

Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic.

Clinical neuropharmacology
2023

Neuroleptic Malignant Syndrome Associated With Lurasidone: A Case Report.

Journal of clinical psychopharmacology
2023

Electrolyte Disturbances Related to Sodium and Potassium and Electroconvulsive Therapy: A Systematic Review.

Journal of clinical medicine
2023

The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome.

Scientific reports
2023

Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report.

Frontiers in psychiatry
2024

A Case of Neuroleptic Malignant Syndrome in the Context of Lithium Toxicity and Aripiprazole Use.

Clinical neuropharmacology
2023

Neuroleptic Malignant Syndrome with Underlying Catatonia - a Case Report.

Psychiatria Danubina
2023

Malignant Tourette's Syndrome in an Adult on Deep Brain Stimulation Presenting With Rhabdomyolysis.

Cureus
2023

Elevated Creatine Phosphokinase in a Patient on a Long-Acting Antipsychotic: A Challenging Presentation Similar to Neuroleptic Malignant Syndrome.

The primary care companion for CNS disorders
2024

Functional propriospinal myoclonus in neuroleptic malignant syndrome.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2023

An Unusual Presentation of Serotonin Syndrome and Subsequent Catatonia in a Patient With a Family History of Huntington's Disease.

Cureus
2023

Neuroleptic Malignant Syndrome After Lithium Withdrawal.

Journal of clinical psychopharmacology
2023

Neuroleptic Malignant Syndrome in a 15-Month-Old Child: A Case Report.

Journal of clinical psychopharmacology
2023

Management of a trauma patient with alcohol withdrawal who developed neuroleptic malignant syndrome in Korea: a case report.

Journal of trauma and injury
2023

A Rare Case of Malignant Syndrome in Parkinson's Disease Caused by Severe Dehydration and Complicated by Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).

Cureus
2023

What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.

Schizophrenia research
2023

COVID-19 Pandemic-Delayed Diagnosis and Treatment of Atypical Neuroleptic Malignant Syndrome in a Violent Forensics Patient With Intellectual Disability and Treatment-Resistant Schizophrenia.

Cureus
2023

Malignant psoas syndrome and bilateral hydronephrosis without evident obstruction in colorectal cancer.

BMJ case reports
2023

The diagnostic dilemma in a patient with neuroleptic malignant syndrome during the COVID-19 pandemic: A significant increase in acute phase reactants.

Clinical case reports
2023

Pharmacological Considerations of Neuroleptic Malignant Syndrome in a Patient on a Long-Acting Antipsychotic.

Journal of the Academy of Consultation-Liaison Psychiatry
2023

Rebound Catatonia Associated With Injectable Paliperidone.

Cureus
2023

Non-Psychosis Symptoms of Clozapine Withdrawal: a Systematic Review.

East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan
2023

Loxapine in the Treatment of Manic and Psychotic Symptoms in an Individual Intolerant to Multiple Mood-Stabilizing and Antipsychotic Medications.

Case reports in psychiatry
2023

Serotonin Syndrome: The Role of Pharmacology in Understanding Its Occurrence.

Cureus
2023

[Central anticholinergic, neuroleptic malignant and serotonin syndromes].

Wiener klinisches Magazin : Beilage zur Wiener klinischen Wochenschrift
2023

The diagnosis and treatment of catatonia.

Clinical medicine (London, England)
2023

Adolescent Aripiprazole-Associated Rhabdomyolysis Without Neuroleptic Malignant Syndrome: A Case Report.

Journal of clinical psychopharmacology
2023

Neuroleptic Malignant Syndrome Improved with Intramuscular Administration of the Anticholinergic Agent, Biperiden.

International medical case reports journal
2023

An Unusual Cause of Persistent Tachycardia: Atypical Neuroleptic Malignant Syndrome.

Cureus
2023

An Atypical Case of Neuroleptic Malignant Syndrome Associated With Ciprofloxacin and Quetiapine.

Cureus
2023

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology.

Journal of psychopharmacology (Oxford, England)
2023

A Case of Neuroleptic Malignant Syndrome Presenting as Anxiety.

Cureus
2023

Rapid symptom control in neuroleptic malignant syndrome with electroconvulsive therapy: A case report.

Frontiers in psychiatry
2023

Neuroleptic malignant syndrome induced by aripiprazole depot.

Neurologia
Ver todos os 1.993 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome de neuroléptico maligno.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome de neuroléptico maligno

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Long-term safety evaluation of mirtazapine: A real-world pharmacovigilance study based on the FAERS database.
    PloS one· 2026· PMID 41790778mais citado
  2. Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
    Brain : a journal of neurology· 2026· PMID 40966690mais citado
  3. A Prospective 1-Year Study of Renal Recovery in Pigment Nephropathy: Insights Beyond the Acute Phase.
    The Journal of the Association of Physicians of India· 2026· PMID 41818093mais citado
  4. Effectiveness of Transdermal Blonanserin Patch for Hyperactive Delirium in Patients with Advanced Cancer Receiving Palliative Care.
    Journal of palliative medicine· 2026· PMID 41766331mais citado
  5. Case Report: Atypical neuroleptic malignant syndrome induced by paliperidone palmitate-diagnostic challenges and clinical considerations.
    Frontiers in psychiatry· 2026· PMID 41756567mais citado
  6. Atypical neuroleptic malignant syndrome without hyperthermia or rigidity in the ıntensive care unit: a diagnostic challenge.
    Acta Neurol Belg· 2026· PMID 41995787recente
  7. Clozapine Withdrawal-Induced Catatonia with Overlapping Features of Neuroleptic Malignant Syndrome: a Case Report.
    Med Arch· 2026· PMID 41939501recente
  8. Malignant Catatonia and Neuroleptic Malignant Syndrome Overlap in the Emergency Department: Diagnostic Challenges and Psychopharmacology Considerations.
    J Clin Psychopharmacol· 2026· PMID 41870353recente
  9. A case report of persistent cerebellar dysfunction following acute lithium toxicity.
    BMC Neurol· 2026· PMID 41803763recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:94093(Orphanet)
  2. MONDO:0019790(MONDO)
  3. GARD:7195(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q1424956(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome de neuroléptico maligno
Compêndio · Raras BR

Síndrome de neuroléptico maligno

ORPHA:94093 · MONDO:0019790
Prevalência
Unknown
Herança
Unknown
CID-10
G21.0 · Síndrome maligna dos neurolépticos
CID-11
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0027849
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades